메뉴 건너뛰기




Volumn 205, Issue 9, 2005, Pages 433-438

Cardiac protection as priority strategy of cardiovascular prevention in high blood pressure;La protección cardíaca como estrategia prioritaria de prevención cardiovascular en hipertensión arterial

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; VALSARTAN;

EID: 27744606997     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1157/13079072     Document Type: Article
Times cited : (1)

References (34)
  • 1
    • 85030726543 scopus 로고    scopus 로고
    • Disponible en: www.ine.es/encuesta de morbilidad hospitalaria
    • Disponible en: www.ine.es/encuesta de morbilidad hospitalaria 2001.
    • (2001)
  • 2
    • 0012376212 scopus 로고    scopus 로고
    • Hypertension with left ventricular hypertrophy/diastolic dysfunction
    • Sleight P, Bakris G, Mancia G, Messerli F, Opie L, editors. Richmond upon Thames (Reino Unido): PAN Communications
    • Barrios V, Ruilope LM. Hypertension with left ventricular hypertrophy/diastolic dysfunction. En: Sleight P, Bakris G, Mancia G, Messerli F, Opie L, editors. Clinical cases in hypertension. Specific treatment strategies (volume two). Richmond upon Thames (Reino Unido): PAN Communications, 2000. p. 16-22.
    • (2000) Clinical Cases in Hypertension. Specific Treatment Strategies , vol.2 , pp. 16-22
    • Barrios, V.1    Ruilope, L.M.2
  • 3
    • 0035089266 scopus 로고    scopus 로고
    • Prognostic implications of left ventricular hypertrophy
    • Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001;141:334-41.
    • (2001) Am. Heart J. , vol.141 , pp. 334-341
    • Vakili, B.A.1    Okin, P.M.2    Devereux, R.B.3
  • 4
    • 0035940391 scopus 로고    scopus 로고
    • Left ventricular hypertrophy as an independient predictor of acute cerebrovascular events in essential hypertension
    • Verdecchia P, Porcellatti C, Reboldi G, Gattobigio R, Borgioni C, Pearson TA, et al. Left ventricular hypertrophy as an independient predictor of acute cerebrovascular events in essential hypertension. Circulation. 2001; 104:2039-44.
    • (2001) Circulation , vol.104 , pp. 2039-2044
    • Verdecchia, P.1    Porcellatti, C.2    Reboldi, G.3    Gattobigio, R.4    Borgioni, C.5    Pearson, T.A.6
  • 5
    • 0033991103 scopus 로고    scopus 로고
    • The influence of antihypertensive drug treatment on the prevention and regression of left ventricular hypertrophy
    • Van Zwieten PA. The influence of antihypertensive drug treatment on the prevention and regression of left ventricular hypertrophy. Cardiovasc Res. 2000;45:82-91.
    • (2000) Cardiovasc. Res. , vol.45 , pp. 82-91
    • Van Zwieten, P.A.1
  • 7
    • 0043164975 scopus 로고    scopus 로고
    • Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol. The Losartan Intervention For Endpoint reduction in hypertension: LIFE study
    • Okin PM, Devereaux RB, Jem S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol. The Losartan Intervention For Endpoint reduction in hypertension: LIFE study. Circulation. 2003;108:684-90.
    • (2003) Circulation , vol.108 , pp. 684-690
    • Okin, P.M.1    Devereaux, R.B.2    Jem, S.3    Kjeldsen, S.E.4    Julius, S.5    Nieminen, M.S.6
  • 8
    • 0035797832 scopus 로고    scopus 로고
    • Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril
    • Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 2001;104:1615-21.
    • (2001) Circulation , vol.104 , pp. 1615-1621
    • Mathew, J.1    Sleight, P.2    Lonn, E.3    Johnstone, D.4    Pogue, J.5    Yi, Q.6
  • 9
    • 0037160968 scopus 로고    scopus 로고
    • Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
    • Dahlof B, Devereaux R, Kjeldesen S, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
    • (2002) Lancet , vol.359 , pp. 995-1003
    • Dahlof, B.1    Devereaux, R.2    Kjeldesen, S.3    Julius, S.4    Beevers, G.5    de Faire, U.6
  • 10
    • 0038642326 scopus 로고    scopus 로고
    • A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension
    • Klingbeil AV, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41-6.
    • (2003) Am. J. Med. , vol.115 , pp. 41-46
    • Klingbeil, A.V.1    Schneider, M.2    Martus, P.3    Messerli, F.H.4    Schmieder, R.E.5
  • 11
    • 0028035369 scopus 로고
    • Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy
    • Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994; 90:1786-93.
    • (1994) Circulation , vol.90 , pp. 1786-1793
    • Levy, D.1    Salomon, M.2    D'Agostino, R.B.3    Belanger, A.J.4    Kannel, W.B.5
  • 12
    • 0031963796 scopus 로고    scopus 로고
    • Prognostic significance of serial changes in left ventricular mass in essential hypertension
    • Verdecchia P, Schillacci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998;97:48-54.
    • (1998) Circulation , vol.97 , pp. 48-54
    • Verdecchia, P.1    Schillacci, G.2    Borgioni, C.3    Ciucci, A.4    Gattobigio, R.5    Zampi, I.6
  • 14
    • 85030730903 scopus 로고    scopus 로고
    • Disponible: en www.ine.es/encuesta de morbilidad hospitalaria
    • Disponible: en www.ine.es/encuesta de morbilidad hospitalaria 2001.
    • (2001)
  • 15
    • 27744437348 scopus 로고    scopus 로고
    • Tratamiento de la cardiopatía hipertensiva
    • Barrios V, editor. Madrid: Momento Médico Iberoamericana
    • Barrios V. Tratamiento de la cardiopatía hipertensiva. En: Barrios V, editor. Hipertensión y corazón. Madrid: Momento Médico Iberoamericana; 2003. p. 53-64.
    • (2003) Hipertensión Y Corazón , pp. 53-64
    • Barrios, V.1
  • 16
    • 0343487983 scopus 로고    scopus 로고
    • Randomised double-blind comparision of placebo an active treatment for older patients with isolated systolic hypertension
    • Staessen JA, Fagard R, Thijs JL, Celis H, Arabidze GG, Birkenhader WH, et al. Randomised double-blind comparision of placebo an active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350: 757-64.
    • (1997) Lancet , vol.350 , pp. 757-764
    • Staessen, J.A.1    Fagard, R.2    Thijs, J.L.3    Celis, H.4    Arabidze, G.G.5    Birkenhader, W.H.6
  • 17
    • 27744531954 scopus 로고    scopus 로고
    • Insuficiencia cardíaca en hipertensión arterial
    • Barrios V, Lozano F. Insuficiencia cardíaca en hipertensión arterial. Enf Vasc Hipertens. 1997;8:5-16.
    • (1997) Enf. Vasc. Hipertens. , vol.8 , pp. 5-16
    • Barrios, V.1    Lozano, F.2
  • 18
    • 0027941077 scopus 로고
    • Left ventricular diastolic dysfunction in hypertension
    • Fouad-Tarazi FM. Left ventricular diastolic dysfunction in hypertension. Curr Opin Cardiol. 1994;551-60.
    • (1994) Curr. Opin. Cardiol. , pp. 551-560
    • Fouad-Tarazi, F.M.1
  • 19
    • 0041408234 scopus 로고    scopus 로고
    • Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial
    • for the CHARM Investigators and Committees
    • Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, et al for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362: 777-81.
    • (2003) Lancet , vol.362 , pp. 777-781
    • Yusuf, S.1    Pfeffer, M.A.2    Swedberg, K.3    Granger, C.B.4    Held, P.5    McMurray, J.J.V.6
  • 20
    • 0029960897 scopus 로고    scopus 로고
    • Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials
    • Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol. 1996;27:1214-8.
    • (1996) J. Am. Coll. Cardiol. , vol.27 , pp. 1214-1218
    • Moser, M.1    Hebert, P.R.2
  • 21
    • 0033034404 scopus 로고    scopus 로고
    • Effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension. The CAPPP randomised trial
    • Hansson L, Lindholm JH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension. The CAPPP randomised trial. Lancet. 1999;353:611-6.
    • (1999) Lancet , vol.353 , pp. 611-616
    • Hansson, L.1    Lindholm, J.H.2    Niskanen, L.3    Lanke, J.4    Hedner, T.5    Niklason, A.6
  • 22
    • 0034688194 scopus 로고    scopus 로고
    • Effects of an angiotensin-converting-enzyme inhibitor, ramipril on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation (HOPE) Study
    • The Heart Outcomes Prevention Evaluation Study Investigators
    • The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation (HOPE) Study. N Engl J Med. 2000;342:145-53.
    • (2000) N. Engl. J. Med. , vol.342 , pp. 145-153
  • 23
    • 0346962877 scopus 로고    scopus 로고
    • Meta-analysis of effectiveness or lack thereof of angiotensin-converting enzyme inhibitors for prevention of heart faliure in patients with systemic hipertension
    • Angeli F, Verdecchia P, Reboldi GP, Gattobigio R, Bentivoglio M, Staessen JA, et al. Meta-analysis of effectiveness or lack thereof of angiotensin-converting enzyme inhibitors for prevention of heart faliure in patients with systemic hipertension. J Am Coll Cardiol. 2004;93:240-3.
    • (2004) J. Am. Coll. Cardiol. , vol.93 , pp. 240-243
    • Angeli, F.1    Verdecchia, P.2    Reboldi, G.P.3    Gattobigio, R.4    Bentivoglio, M.5    Staessen, J.A.6
  • 24
    • 0025942936 scopus 로고
    • Morbidity and mortality in the Swedish trial in older patients with hypertension
    • Dahlöf B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO, et al. Morbidity and mortality in the Swedish trial in older patients with hypertension. Lancet. 1991;338:1281-5.
    • (1991) Lancet , vol.338 , pp. 1281-1285
    • Dahlöf, B.1    Lindholm, L.H.2    Hansson, L.3    Schersten, B.4    Ekbom, T.5    Wester, P.O.6
  • 25
    • 0000220739 scopus 로고
    • Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension
    • SHEP Cooperative Research Group
    • SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1991;266:3255-64.
    • (1991) JAMA , vol.266 , pp. 3255-3264
  • 26
    • 0029886630 scopus 로고    scopus 로고
    • Blood pressure as a cardiovascular risk factor
    • Kannel WB. Blood pressure as a cardiovascular risk factor. JAMA. 1996;275:1571-6.
    • (1996) JAMA , vol.275 , pp. 1571-1576
    • Kannel, W.B.1
  • 27
    • 85030732600 scopus 로고    scopus 로고
    • Outcomes in hypertensive patients at high cardiovascular risk treated with regimens base don valsartan or amlodipine: The VALUE randomised trial
    • Published online June 14, Disponible en:
    • Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens base don valsartan or amlodipine: the VALUE randomised trial. Published online June 14, 2004. Disponible en: http://image.thelancet.com/extras/04art4187web.pdf
    • (2004)
    • Julius, S.1    Kjeldsen, S.E.2    Weber, M.3    Brunner, H.R.4    Ekman, S.5    Hansson, L.6
  • 28
    • 1942520942 scopus 로고    scopus 로고
    • Stroke prevention, blood cholesterol and statins
    • Amarenco P, Lavallee P, Touboul PJ. Stroke prevention, blood cholesterol and statins. Lancet Neurol. 2004;3(5):271-8.
    • (2004) Lancet Neurol. , vol.3 , Issue.5 , pp. 271-278
    • Amarenco, P.1    Lavallee, P.2    Touboul, P.J.3
  • 29
    • 2642626655 scopus 로고    scopus 로고
    • Economic consequences of diabetes mellitus in the US in 1997
    • American Diabetes Association
    • American Diabetes Association. Economic consequences of diabetes mellitus in the US in 1997. Diabetes Care. 1998;21:269-309.
    • (1998) Diabetes Care , vol.21 , pp. 269-309
  • 30
    • 0032511580 scopus 로고    scopus 로고
    • Tight blood pressure control and risk of cardiovascular and microvascular complications in type 2 diabetes: UKPDS 38
    • UK Prospective Diabetes Study (UKPDS) Group
    • UK Prospective Diabetes Study (UKPDS) Group Tight blood pressure control and risk of cardiovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-13.
    • (1998) BMJ , vol.317 , pp. 703-713
  • 31
    • 0028299731 scopus 로고
    • Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study
    • Benjamín EJ, Levy D, Vais SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271:840-4.
    • (1994) JAMA , vol.271 , pp. 840-844
    • Benjamín, E.J.1    Levy, D.2    Vais, S.M.3    D'Agostino, R.B.4    Belanger, A.J.5    Wolf, P.A.6
  • 32
    • 0020074665 scopus 로고
    • Epidemiological features of chronic atrial fibrillation: The Framingham Study
    • Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiological features of chronic atrial fibrillation: the Framingham Study. N Engl J Med. 1982;306:1018-22.
    • (1982) N. Engl. J. Med. , vol.306 , pp. 1018-1022
    • Kannel, W.B.1    Abbott, R.D.2    Savage, D.D.3    McNamara, P.M.4
  • 33
    • 0027437748 scopus 로고
    • Asymptomatic ventricular arrhythmias and mortality risk in subjects with left ventricular hypertrophy
    • Bikkina M, Larson MG, Benjamin EJ, Levy D. Asymptomatic ventricular arrhythmias and mortality risk in subjects with left ventricular hypertrophy. J Am Coll Cardiol. 1993;22:1111-6.
    • (1993) J. Am. Coll. Cardiol. , vol.22 , pp. 1111-1116
    • Bikkina, M.1    Larson, M.G.2    Benjamin, E.J.3    Levy, D.4
  • 34
    • 0028800258 scopus 로고
    • Evidence favoring the hipothesis that ventricular arrhythmias have prognosis significance in left ventricular hypertrophy secondary to systemic hipertensión
    • Almendral J, Villacastín JP, Arenal A, Tercedor L, Merino JL, Delcán JL. Evidence favoring the hipothesis that ventricular arrhythmias have prognosis significance in left ventricular hypertrophy secondary to systemic hipertensión. Am J Cardiol 1995;76 Suppl D:D60-3.
    • (1995) Am. J. Cardiol. , vol.76 , Issue.SUPPL. D
    • Almendral, J.1    Villacastín, J.P.2    Arenal, A.3    Tercedor, L.4    Merino, J.L.5    Delcán, J.L.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.